Navigation Links
Amarin to Present at UBS Life Sciences Conference
Date:9/16/2010

DUBLIN and MYSTIC, Conn., Sept. 16 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that John Thero, Chief Financial Officer, is scheduled to present on Amarin's behalf at the Global UBS Life Sciences Conference on Wednesday, September 22, 2010 at 12:30 pm. This conference will be held at the Grand Hyatt New York in New York City. Colin Stewart, recently appointed as President and Chief Executive Officer, will also be at the conference representing Amarin in meetings with investors.

A live audio webcast of the presentation will be available at the following URL:  

http://cc.talkpoint.com/ubsx001/092110a_lv/?entity=138_8G1X8RK

About AmarinAmarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), which is presently being investigated in two Phase 3 clinical trials, one for the treatment of patients with very high triglyceride levels and the other for the treatment of patients with high triglycerides with mixed dyslipidemia on statin therapy. Both of these Phase 3 trials are conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.Contacts:Investor Contact Information: John F. TheroChief Financial OfficerIn US: +1 (860) 572 4979 investor.relations@amarincorp.comLee M. SternThe Trout GroupIn U.S. +1 (646) 378-2922lstern@troutgroup.comInternat
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
2. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
3. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
4. Generex Announces Presentations of Novel Vaccine Strategies
5. Metabolic Solutions Development Company to Present Research Findings to European Association for the Study of Diabetes
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at UBS Global Life Sciences Conference
7. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
8. Sono-Tek Presents at the 15th International Coating Science and Technology Symposium (ISCST, St. Paul, MN)
9. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
10. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
11. BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Reportlinker.com announces that a new market research report ... Merger and Acquisition Terms and Agreements in ... http://www.reportlinker.com/p0306576/Merger-and-Acquisition-Terms-and-Agreements-in-Pharma-Biotech-and-Diagnostics-4th-edition.html ... analysis of how and why companies enter merger ...
... Oct. 7 Sunridge International (OTC Bulletin Board: ... Trabeculoplasty (PNT) non-invasive treatment for glaucoma and ocular hypertension, ... by Beijing Vision World Trading Co. Ltd. (BVW), in ... patient research studies before gaining regulatory approval by China,s ...
Cached Medicine Technology:Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 2Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 3Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 4Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 5Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 6Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 7Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 8Sunridge Advances its PNT Glaucoma Treatment Throughout China 2
(Date:7/9/2014)... innovative tool that captures heretofore hidden ways that cells ... protein that makes breast cancer cells more likely to ... cancer,s spread in part by blocking two other proteins ... suggests these two disease processes could have unexpected ties. ... 10 issue of Nature , points to the ...
(Date:7/9/2014)... in Russia might contribute to HIV transmission and ... researchers from Boston University Schools of Medicine and ... State University, sought to discover the effect police ... cohort of HIV-positive people with lifetime of injection ... police were more likely to share needlesincreasing HIV ...
(Date:7/9/2014)... YORK (July 8, 2014) Researchers from Montefiore ... of Medicine of Yeshiva University will present new ... held July 12 July 17 in Copenhagen, Denmark. ... that could prompt transition from cognitive normality to mild ... the Einstein Aging Study , established in 1980 ...
(Date:7/9/2014)... most important organs in the human body. Its job ... this is its synthesis function and that ... is its detoxification function. Lack of exercise and too ... liver. The resulting diseased cells can lead to inflammations, ... According to the German Liver Foundation, over five million ...
(Date:7/9/2014)... Qubec City, July 9, 2014 A study published ... Yves De Koninck and Robert Bonin, two researchers at ... pain hypersensitivity using a new method that involves rekindling ... discovery could lead to novel means to alleviate chronic ... at Universit Laval and Institut universitaire en sant mentale ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2
... screening to identify lung tumors likely to respond ... drugs as first-line treatment rather than after standard ... Massachusetts General Hospital Cancer Center investigators found that ... for non-small-cell-lung-cancer (NSCLC), additional research is required before ...
... the ... chance to change people,s lives, OTTAWA, May 20 ... for new ways to make the most of their,time, especially ... independent marketing opportunities provided by,Melaleuca, The Wellness Company(R)., One ...
... May 20 Wednesday, May 21, 2008,Easter Seals Greater ... Mary Landrieu and Capital One for,their efforts on behalf ... Awards Benefit will be held at the JW Marriott ... and dinner at 7:00,pm. Gordon Peterson of WJLA TV ...
... per patient , , TUESDAY, May 20 (HealthDay News) ... latent tuberculosis saves time, money and lives, new research ... of four months of Rifampin instead of the current ... health-care system," lead analyst Anne Aspler, of the respiratory ...
... May 20 The retiring baby boomers,have challenged ... Moreover, the multi-generational workforce is challenging,companies across all ... to define a new type of leader., ... new thinking,around leadership models, discover fast-acting tactics and ...
... idiopathic pulmonary fibrosis (IPF) may have a new treatment ... Phase III, double-blind, placebo-controlled clinical trial, the investigators discovered ... progression of IPF, reducing the loss of lung capacity. ... Societys 2008 International Conference in Toronto on Tuesday, May ...
Cached Medicine News:Health News:Determining genetic signature of lung tumors can help guide treatment 2Health News:Determining genetic signature of lung tumors can help guide treatment 3Health News:Lucrative Sales Opportunities Abound With Melaleuca, The Wellness Company(R) 2Health News:New Latent TB Drug Saves Lives, Money 2Health News:Fortune 500s to Convene in Florida, Sharing Insights & Best Practices for Developing Tomorrow's Leaders 2Health News:New treatment gives hope for pulmonary fibrosis patients 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: